Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority studyJean‐Michel Molina, Steven L. Chuck, Nathan Clumeck et al.|The Lancet Infectious Diseases|2011Cited by 172
Activity of Elvitegravir, a Once‐Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose‐Ranging Clinical TrialAndrew Zolopa, Andrew Cheng, Daniel S Berger et al.|The Journal of Infectious Diseases|2010Cited by 114